

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### Subcutaneous interferon-beta, neurological complications of COVID-19, TGA approval for RONAPREVE (casirivimab + imdevimab)

#### Peer reviewed journals featured:

- Systematic reviews on:
  - The efficacy of subcutaneous interferon-beta in COVID-19 [here](#)
  - Comparing the clinical efficacy of COVID-19 vaccines [here](#)
- A randomised controlled trial on neutralisation of SARS-CoV-2 variants in transplant recipients after two or three doses of Spikevax (Moderna) vaccine [here](#)
- Narrative reviews on:
  - Neurological complications and infection mechanism of SARS-CoV-2 [here](#)
  - Zero-COVID, risk and health disparities [here](#)
- Observational studies on:
  - Seroprevalence of SARS-CoV-2 antibodies among children in Montreal [here](#)
  - Comparison of mortality risk evaluation tools in critically ill COVID-19 patients [here](#)

#### Letters and correspondence discussed:

- Antibody response to Comirnaty (Pfizer) vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy [here](#)
- Risks of SARS-CoV-2 breakthrough infection and hospitalisation in fully vaccinated patients with multiple myeloma [here](#)

#### Guidance and reports

- The World Health Organization published:
  - A clinical training module on casirivimab and imdevimab for COVID-19 [here](#)
  - An update on COVID-19 and influenza [here](#)
  - Updated living guidance for clinical management of COVID-19 [here](#)
  - Its weekly COVID-19 epidemiological report [here](#), COVID-19 vaccine tracker [here](#), and COVID-19 operational report [here](#)
- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)
- The Therapeutic Goods Administration (TGA) issued provisional approval to RONAPREVE (casirivimab + imdevimab) for COVID-19 treatment [here](#)

## News and blogs

- COVID-19 vaccines protective effect against post-acute COVID-19 syndrome [here](#)
- COVID-19 vaccine highly effective against adolescent hospitalisations [here](#)

[Click here](#) to subscribe to the daily evidence digest.

### Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).